DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tamiflu (Oseltamivir Phosphate) - Summary



TAMIFLU (oseltamivir phosphate) is an antiviral agent indicated for treatment and prophylaxis of influenza.

Treatment of Influenza

TAMIFLU is indicated for the treatment of uncomplicated acute illness due to influenza infection in patients 1 year and older who have been symptomatic for no more than 2 days.

Prophylaxis of Influenza

TAMIFLU is indicated for the prophylaxis of influenza in adult patients and adolescents 13 years and older.

TAMIFLU is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee.

See all Tamiflu indications & dosage >>


Media Articles Related to Tamiflu (Oseltamivir)

Pediatric Flu: One Size Does Not Fit All
Source: MedPage Today Emergency Medicine [2015.01.20]
(MedPage Today) -- Controversy continues over oseltamivir, but dont throw the baby out with the bathwater

more news >>

Published Studies Related to Tamiflu (Oseltamivir)

Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. [2014]
urban setting in Bangladesh... INTERPRETATION: Oseltamivir treatment resulted in a modest reduction in the

Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. [2013]
Given the limited understanding about pharmacokinetic-pharmacodynamic (PK-PD) determinants of oseltamivir efficacy, data from two phase 2 influenza virus inoculation studies were evaluated. Healthy volunteers in studies 1 and 2 were experimentally infected with influenza A/Texas (the concentration of neuraminidase inhibitor which reduced neuraminidase activity by 50% [IC(50)] = 0.18 nM) or B/Yamagata (IC(50) = 16.76 nM), respectively.

Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). [2011.09]
BACKGROUND: Detailed pharmacokinetics to guide oseltamivir (Tamiflu(R)) dosing in morbidly obese patients is lacking... CONCLUSIONS: With single and multiple dosing, the systemic exposure to oseltamivir is decreased but that of oseltamivir carboxylate is largely unchanged. Based on these pharmacokinetic data, an oseltamivir dose adjustment for body weight would not be needed in morbidly obese individuals.

Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. [2011.09]
We previously showed that oseltamivir, a prodrug of the influenza virus neuraminidase inhibitor Ro 64-0802, is a substrate of proton-coupled oligopeptide transporter (PEPT1), and its intestinal absorption in rats is markedly inhibited by administration with milk...

Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. [2011.08.16]
BACKGROUND: Observational studies from Asia suggest that maxingshigan-yinqiaosan may be effective in the treatment of acute H1N1 influenza. OBJECTIVE: To compare the efficacy and safety of oseltamivir and maxingshigan-yinqiaosan in treating uncomplicated H1N1 influenza... CONCLUSION: Oseltamivir and maxingshigan-yinqiaosan, alone and in combination, reduced time to fever resolution in patients with H1N1 influenza virus infection. These data suggest that maxingshigan-yinqiaosan may be used as an alternative treatment of H1N1 influenza virus infection. PRIMARY FUNDING SOURCE: Beijing Science and Technology Project and Beijing Nova Program.

more studies >>

Clinical Trials Related to Tamiflu (Oseltamivir)

Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies. [Completed]
Objective 1: Determine the safety and toxicity profile of Tamiflu administered in combination with probenecid in healthy adults. Objective 2: Determine the pharmacokinetic profile of Tamiflu and probenecid in healthy adults.

Pharmacokinetics of TamifluŽ (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD) [Recruiting]
Critically ill patients with flu may receive a drug called oseltamivir. They may also receive medical therapies to support their lung function (extracorporeal membrane oxygenation; ECMO) and kidney function (continuous venovenous hemodialysis; CVVHD). CVVHD and ECMO may remove some oseltamivir from the bloodstream. The purpose of this study is to determine how much oseltamivir gets removed by CVVHD or ECMO in critically ill patients.

A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain [Recruiting]
This randomized, double-blind, multi-center study of Tamiflu (Oseltamivir) will evaluate the efficacy against viral activity, the effectiveness in resolving the disease symptoms, and the safety and tolerability in patients with influenza. Patients with (H1N1) 2009 influenza strain or influenza A are eligible for this study. Patients will be randomized to one of four treatment regimens. Patients will receive oral doses of either 75 mg (adults) or 150 mg (adults) of study drug twice daily for 5 or 10 consecutive days. The dose will be body weight-adjusted for pediatric patients. The target sample size is 300-500 patients.

Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine [Completed]
This study is designed to assess the safety and pharmacokinetic effects of oseltamivir administration alone or in combination with amantadine in healthy volunteers.

Efficacy Study of Early vs. Late Oseltamivir Administration for Treating and Preventing Influenza [Active, not recruiting]
This study is a randomized, blinded, placebo-controlled clinical efficacy trial to assess the duration and severity of influenza symptoms, duration of viral shedding, and household transmission in influenza patients receiving oseltamivir early and late relative to placebo.

There are four main hypotheses:

1. The duration of influenza symptoms, severity, and duration of viral shedding are reduced in patients who start oseltamivir treatment late (48 to 119 hours after illness onset) compared to those receiving no antiviral therapy;

2. Antiviral effectiveness for reducing infectiousness to household contacts is at least 80% for index cases starting therapy early (<48 hours) compared to those receiving no antiviral therapy;

3. Antiviral effectiveness for reducing infectiousness to household contacts is at least 60% when patients initiate treatment late (48 to 119 hours) compared to those receiving no antiviral therapy;

4. Prior influenza vaccination during the same season reduces the duration of influenza symptoms and symptom severity in patients receiving oseltamivir after adjusting for age and timing of antiviral therapy (early vs. late).

There are two secondary hypotheses:

1. The duration of influenza symptoms, severity, and duration of viral shedding are reduced in patients with influenza who start oseltamivir treatment early (within 48 hours) vs. late (48 to 119 hours);

2. The incidence of secondary complications is lower in patients starting oseltamivir therapy late relative to those receiving no antiviral therapy.

more trials >>

Reports of Suspected Tamiflu (Oseltamivir) Side Effects

Abnormal Behaviour (53)Overdose (49)Maternal Exposure During Pregnancy (33)Pneumonia (30)Influenza (29)Hallucination (22)Vomiting (20)Pregnancy (20)NO Adverse Event (19)Acute Respiratory Distress Syndrome (18)more >>


Based on a total of 10 ratings/reviews, Tamiflu has an overall score of 7.20. The effectiveness score is 7.60 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.

Tamiflu review by 52 year old female patient

Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   family flu outbreak
Dosage & duration:   75mg taken twice x a day for the period of 5 days
Other conditions:   none
Other drugs taken:   none
Reported Results
Benefits:   My son came home from college with the flu. Student Health gave him a pack of Tamiflu and he felt better within 24 hours. When I started feeling sick 3 days later, I called my Dr and ask for Tamiflu. I felt almost back to norma lwithin 24 hours.
Side effects:   none
Comments:   Just took the pill and drank fluids


Tamiflu review by 40 year old female patient

Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   The flu
Dosage & duration:   75 mg capsules taken twice per day for the period of 5 days
Other conditions:   none
Other drugs taken:   none
Reported Results
Benefits:   This is an easy to take flu remedy that lasts only 5 days. It was good to know that as miserable as the flu was, I could finally take action to rid myself of it sooner, as compared to last year when there was no remedy available. By taking Tamiflu, I think the duration of the flu may have been shortened by 1-2 days
Side effects:   none
Comments:   I was hoping that I would feel my flu symptoms lessening on the first day of treatment. I didn't feel significantly better until the third day. This prescription cost close to $100. It makes me wonder if it was really worth it.


Tamiflu review by 25 year old female patient

Overall rating:  
Effectiveness:   Marginally Effective
Side effects:   Severe Side Effects
Treatment Info
Condition / reason:   i was in a risk group - frontline pharmacist
Dosage & duration:   one jab (dosage frequency: once) for the period of once
Other conditions:   numbness in arm, cold, fever
Other drugs taken:   none
Reported Results
Benefits:   supposed prevention of catching swine flu
Side effects:   sickness for 4 days, numb arm for that period of time, couldn't dress, couldn't drive. then cold anf flu followed, with stomach problams because of lack of food because of associated problems
Comments:   no treatment was given except cold anf flu medication, just waited out the symptoms and side effects

See all Tamiflu reviews / ratings >>

Page last updated: 2015-01-20

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014